Reuters logo
BRIEF-Portola Pharmaceuticals says FDA accepts NDA for priority review for betrixaban
December 23, 2016 / 7:24 PM / a year ago

BRIEF-Portola Pharmaceuticals says FDA accepts NDA for priority review for betrixaban

Dec 23 (Reuters) - Portola Pharmaceuticals Inc -

* Portola Pharmaceuticals announces FDA accepts New Drug Application for priority review and EMA validates marketing authorization application for oral, Factor Xa inhibitor anticoagulant betrixaban

* Portola Pharmaceuticals Inc says has been given a Prescription Drug User Fee Act (PDUFA) action date of June 24, 2017

* Portola Pharmaceuticals-EMA validated MAA for betrixaban for extended-duration prophylaxis of VTE in adults with acute medical illness,risk factors Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below